Professor, Department of Urology
Professor, Department of Physiology & Biophysics
Dr. Kelvin Davies joined the Einstein Department of Urology in 2001 as a basic scientist with a research background in biochemistry and molecular biology. Since 2009 he has had a joint faculty position in the Departments of Physiology and Biophysics. Overall his research applies biochemical and molecular mechanisms to understand urogenital pathology, particularly the role of smooth muscle in the development of urogenital pathology. The primary goal of these basic science studies is clinical translation and Dr. Davies’s work has resulted in the first and only FDA approved clinical trials of gene therapy to treat benign urologic disease (over-active bladder and erectile dysfunction (ED)).
At present the two major interests of his lab are the role of potassium channels in bladder and erectile function, and the role of opiorphin is erectile physiology and priapism. Collaboration with other researchers has been a hallmark of Dr. Davies’s research and he has collaborated and published with several other researchers at Einstein in such diverse areas as the use of NO-encapsulating nanoparticles for treatment of ED, peripheral nerve regeneration as a possible treatment for ED resulting from nerve damage associated with radical prostatectomy, the role of opiorphins in prostate cancer and the impact of opiorphins synthesized in the erectile tissue on systemic blood-pressure as a potential link between ED and cardiovascular disease.
His work has been funded by several grants; he has been Principal Investigator on 7 NIH grants and is currently Principal Investigator on an NIH R01 and two NY State Department of Health grants.
Publications since 2014
1) Fu, S. Tar, M.T., Melman, A. and Davies, K.P. (2014) Opiorphin is a master regulator of the hypoxic response in corporal smooth muscle cells. FASEB Journal, 28(8):3633-44
2) ) Wang, Y., Tar, M.T., Wang, H.Z., Fu, S., Melman, A. and Davies, K.P. (2014) Diabetes induced changes in tension and phasic contractions of isolated bladder strips correlate with modulated Kv7 channel activity. International Journal of Urology, 21(10):1059-64.
3) Tar, M.T., Martinez, L.R., Nosanchuk, J.D. and Davies, K.P. (2014) An animal model for the effects of methamphetamine on erectile function. Andrology 2(4):531-6
4) Bosler, J., Davies K.P. and Neal-Perry, G. (2014) Peptides in Seminal Fluid and their Role in Infertility: A potential role for opiorphin inhibition of neutral endopeptidase activity as a factor in sperm motility. Reproductive Sciences. 21(11):1334-40.
5) Tar, M.T., Cabrales, P., Mahantesh, N., Nacharaju, P., Friedman, A., Friedman, J. and Davies, K.P. (2014) Nanoparticles encapsulating NO can increase intracorporal pressure and elicit spontaneous erections in a rat model of radical prostatectomy. J Sex Med 11(12) 2903-14. PMID: 25302850
6) Fu, S., Davies, K.P. (2015) Opiorphin-dependent upregulation of CD73 (a key enzyme in the adenosine signaling pathway) in corporal smooth muscle cells exposed to hypoxic conditions and in corporal tissue in pre-priapic sickle cell mice. Int J Impot Res. 27(4); 140-5. PMID: 25833166
7) Davies, K.P. (2015) Development and therapeutic applications of nitric oxide releasing materials to treat erectile dysfunction. Future Science OA.1(1): FSO53.PMID: 27019746.
8) Musicki, B., Bella, A.J., Bivalacqua, T.J., Davies, K.P., DiSanto, M.E., Gonzalez-Cadavid, N.F., Hannan, J.L., Kim, N.N., Podlasek, C.A., Wingard, C.J. and Burnett, A.L. (2015) Basic Science Evidence for the Link Between Erectile Dysfunction and Cardiometabolic Dysfunction. J Sex Med. 12(12):2233-55. PMID: 26646025.
9) Ahmadi, M, Lee, H.H., Sanchez D.A., Friedman A.J., Tar M.T., Davies K.P., Nosanchuk J.D., Martinez, L.R. (2016) Sustained nitric oxide releasing nanoparticles induce cell death in Candida albicans yeast and hyphal cells preventing biofilm formation in vitro and in a rodent central venous catheter model. Antimicrob Agents Chemother. [Epub ahead of print] PMID: 26810653
10) Stern, J.M., Moazami, S., Qiu,Y., Kurland, I. Chen, Z., Agalliu, I., Burk, R., Davies, K.P. (2016) Evidence for a Distinct Gut Microbiome in Kidney Stone Formers Compared to Non-stone Formers (In Press).
Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.
Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Forchheimer Building, Room 742
Bronx, NY 10461
BBC features research by Kelvin Davies, Ph.D., and Joel Friedman, M.D., Ph.D., that highlights using nanoparticles to treat erectile dysfunction.
The Sunday Times (UK) interviews Kelvin Davies, Ph.D., on his involvement in a study that used an innovative new drug-delivery system—nanoparticles infused with nitric oxide and applied topically---to successfully treat erectile dysfunction in animals. The nanoparticle technology was developed by Joel M. Friedman, M.D., Ph.D., professor of physiology & biophysics and of medicine at Einstein and his son, Adam Friedman, M.D., a resident in dermatology in Einstein’s department of medicine. The findings received extensive press coverage at the annual meeting of the American Urological Association on April 26, 2009.